Total costs of inpatient treatment for COVID-19 in a tertiary hospital in Serbia.

IF 0.3 4区医学 Q3 MEDICINE, GENERAL & INTERNAL Hippokratia Pub Date : 2022-04-01

P S Sazdanovic, S Milisavljevic, D R Milovanovic, S M Jankovic, D Baskic, Ristic Ignjatovic, Zecevic Ruzic, Lucic Tomic, N Djordjevic, D Jovanovic, A Stojkovic, T Lazarevic, Cvetkovic Begovic, M J Kostic

{"title":"Total costs of inpatient treatment for COVID-19 in a tertiary hospital in Serbia.","authors":"P S Sazdanovic, S Milisavljevic, D R Milovanovic, S M Jankovic, D Baskic, Ristic Ignjatovic, Zecevic Ruzic, Lucic Tomic, N Djordjevic, D Jovanovic, A Stojkovic, T Lazarevic, Cvetkovic Begovic, M J Kostic","doi":"","DOIUrl":null,"url":null,"abstract":"Background: Our study aimed to identify the total costs of inpatient treatment for coronavirus disease 2019 (COVID-19) in a tertiary institution in Serbia, an upper-middle-income country in Southeast Europe.Methods: An observational, retrospective, cost-of-illness study was performed from the perspective of the National Health Insurance Fund and included a cohort of 78 females and 118 males admitted to the COVID-19 ward units of a tertiary center during the first wave of the pandemic.Results: The median of the total costs in the non-survivors subgroup (n =43) was 3,279.16 Euros [interquartile range (IQR): 4,023.34; range: 355.20-9,909.61) which is higher than in the survivors (n =153) subgroup 747.10 Euros (IQR: 1,088.21; 46.71-3,265.91). The cut-off value of 156.46 Euros regarding the total costs per day was estimated to have 95.3 % sensitivity and 91.5 % specificity for predicting patients' dismal prognosis, with the area under the curve (AUC) of 0.968 (95 % confidence interval: 0.940-0.996, p <0.001).Conclusions: Direct medical inpatient treatment costs for COVID-19 represent a significant economic burden. The link between increased costs and an ultimate unfavorable outcome should be further explored.HIPPOKRATIA 2022, 26 (2):62-69.","PeriodicalId":50405,"journal":{"name":"Hippokratia","volume":"26 2","pages":"62-69"},"PeriodicalIF":0.3000,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177856/pdf/hippokratia-26-62.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hippokratia","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Our study aimed to identify the total costs of inpatient treatment for coronavirus disease 2019 (COVID-19) in a tertiary institution in Serbia, an upper-middle-income country in Southeast Europe.

Methods: An observational, retrospective, cost-of-illness study was performed from the perspective of the National Health Insurance Fund and included a cohort of 78 females and 118 males admitted to the COVID-19 ward units of a tertiary center during the first wave of the pandemic.

Results: The median of the total costs in the non-survivors subgroup (n =43) was 3,279.16 Euros [interquartile range (IQR): 4,023.34; range: 355.20-9,909.61) which is higher than in the survivors (n =153) subgroup 747.10 Euros (IQR: 1,088.21; 46.71-3,265.91). The cut-off value of 156.46 Euros regarding the total costs per day was estimated to have 95.3 % sensitivity and 91.5 % specificity for predicting patients' dismal prognosis, with the area under the curve (AUC) of 0.968 (95 % confidence interval: 0.940-0.996, p <0.001).

Conclusions: Direct medical inpatient treatment costs for COVID-19 represent a significant economic burden. The link between increased costs and an ultimate unfavorable outcome should be further explored.HIPPOKRATIA 2022, 26 (2):62-69.

Abstract Image

微信好友朋友圈 QQ好友复制链接

本刊更多论文

塞尔维亚一家三级医院新冠肺炎住院治疗的总费用。

背景：我们的研究旨在确定东南欧中高收入国家塞尔维亚一家三级机构2019冠状病毒病（新冠肺炎）住院治疗的总费用，疾病成本研究是从国家健康保险基金的角度进行的，包括第一波疫情期间入住三级中心新冠肺炎病房的78名女性和118名男性。结果：非幸存者亚组（n=43）的总成本中位数为3279.16欧元[四分位间距（IQR）：4023.34；范围：355.20-9909.61]，高于幸存者（n=153）亚组747.10欧元（IQR:108.821；46.71-3265.91）关于每天总费用的156.46欧元的截止值估计对预测患者的不良预后具有95.3%的敏感性和91.5%的特异性，曲线下面积（AUC）为0.968（95%置信区间：0.940-0.996，p结论：新冠肺炎的直接住院治疗费用代表了巨大的经济负担。应进一步探索费用增加与最终不利结果之间的联系。HIPPOKRATIA 2022，26（2）：62-69。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Hippokratia MEDICINE, GENERAL & INTERNAL-

CiteScore

1.10

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Hippokratia journal is a quarterly issued, open access, peer reviewed, general medical journal, published in Thessaloniki, Greece. It is a forum for all medical specialties. The journal is published continuously since 1997, its official language is English and all submitted manuscripts undergo peer review by two independent reviewers, assigned by the Editor (double blinded review process). Hippokratia journal is managed by its Editorial Board and has an International Advisory Committee and over 500 expert Reviewers covering all medical specialties and additionally Technical Reviewers, Statisticians, Image processing Experts and a journal Secretary. The Society “Friends of Hippokratia Journal” has the financial management of both the printed and electronic edition of the journal.